Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics (NASDAQ:OVID) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Which has more risk and volatility, OVID or CRBP?

Ovid Therapeutics has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in OVID or CRBP?

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 13.1% of Ovid Therapeutics shares are held by insiders. Comparatively, 3.6% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor OVID or CRBP?

In the previous week, Ovid Therapeutics had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 3 mentions for Ovid Therapeutics and 2 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.71 beat Ovid Therapeutics' score of 0.92 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has higher earnings and valuation, OVID or CRBP?

Ovid Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$548K	52.55	-$26.43M	-$0.35	-1.16
Corbus Pharmaceuticals	N/A	N/A	-$40.21M	-$4.22	-1.96

Do analysts recommend OVID or CRBP?

Ovid Therapeutics presently has a consensus target price of $3.13, suggesting a potential upside of 671.60%. Corbus Pharmaceuticals has a consensus target price of $50.88, suggesting a potential upside of 515.18%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Corbus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Corbus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10

Is OVID or CRBP more profitable?

Corbus Pharmaceuticals has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -4,562.23%. Ovid Therapeutics' return on equity of -34.17% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-4,562.23%	-34.17%	-25.34%
Corbus Pharmaceuticals	N/A	-36.87%	-32.87%

Summary

Ovid Therapeutics beats Corbus Pharmaceuticals on 11 of the 15 factors compared between the two stocks.